- $86.56m
- -$6.16m
- 18
- 27
- 67
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.19 | ||
| Price to Tang. Book | 1.19 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -171.9% | ||
| Return on Equity | -121.68% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.
Directors
- Daniel Janney NEC (55)
- Adam Tomasi PRE (51)
- Robert Alexander CEO (51)
- Baird Radford CFO
- Mark Asbury GCN (57)
- Craig Paterson OTH
- Robert Andreatta IND (59)
- Steven James IND (63)
- John Mckearn IND (67)
- Paul Walker IND (46)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- March 9th, 2012
- Public Since
- July 19th, 2018
- No. of Shareholders
- 12
- No. of Employees
- 131
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 89,343,634
- Address
- 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS, 94070
- Web
- https://www.allakos.com/
- Phone
- +1 6505975002
- Auditors
- Ernst & Young LLP
Upcoming Events for ALLK
Q1 2025 Allakos Inc Earnings Release
Allakos Inc Annual Shareholders Meeting
Similar to ALLK
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Allakos share price?
As of Today at 18:11 UTC, shares in Allakos are trading at $0.97. This share price information is delayed by 15 minutes.
How has the Allakos share price performed this year?
Shares in Allakos last closed at $0.97 and the price had moved by -68.44% over the past 365 days. In terms of relative price strength the Allakos share price has underperformed the S&P500 Index by -74.09% over the past year.
What are the analyst and broker recommendations for Allakos?
The overall consensus recommendation for Allakos is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Allakos dividend yield?
Allakos does not currently pay a dividend.
Does Allakos pay a dividend?
Allakos does not currently pay a dividend.
When does Allakos next pay dividends?
Allakos does not currently pay a dividend.
How do I buy Allakos shares?
To buy shares in Allakos you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Allakos?
As of the previous close price of $0.97, shares in Allakos had a market capitalisation of $86.56m.
Where are Allakos shares listed?
Here are the trading details for Allakos:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ALLK
What kind of share is Allakos?
Based on an overall assessment of its quality, value and momentum Allakos is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Allakos share price forecast for 2025?
The analyst consensus target price for shares in Allakos is $3.35. That is 245.79% above the last closing price of $0.97.
Analysts covering Allakos currently have a consensus Earnings Per Share (EPS) forecast of -$1.50 for the next financial year.
Find out moreWhat is the trend in the Allakos share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allakos. Over the past six months, its share price has outperformed the S&P500 Index by +8.83%.
As of the last closing price of $0.97, shares in Allakos were trading -2.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Allakos PE Ratio?
The Allakos PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.97.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Allakos?
Allakos' management team is headed by:
- Daniel Janney - NEC
- Adam Tomasi - PRE
- Robert Alexander - CEO
- Baird Radford - CFO
- Mark Asbury - GCN
- Craig Paterson - OTH
- Robert Andreatta - IND
- Steven James - IND
- John Mckearn - IND
- Paul Walker - IND